<a href="https://www.fiercebiotech.com/biotech/terremoto-takes-108m-series-c-fuel-clinical-trials-akt1-inhibitors" hreflang="en">Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitors</a>
fiercebiotech.com·Apr 15, 2026
Terremoto Biosciences plans to utilize its $108 million series C funding to expand its research and development in covalent drug discovery.
For someone interested in biotech and AI drug discovery, the key learning is that Terremoto Biosciences' $108 million Series C funding round is a strong signal of investor confidence in expanding the covalent drug alphabet, which could lead to novel therapeutic pathways and opportunities for partnerships or collaborations in precision medicine and AI-driven drug development.